| Dr John Cooke, MD | |
|
516 Bloomfield Ave, Suite 4, Montclair, NJ 07042-3429 | |
| (973) 509-1500 | |
| (973) 509-1919 |
| Full Name | Dr John Cooke |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 516 Bloomfield Ave, Montclair, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083895114 | NPI | - | NPPES |
| 8256004 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 25MA07095800 (New Jersey) | Primary |
| Entity Name | John Cooke Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083035497 PECOS PAC ID: 1759703788 Enrollment ID: O20200622001078 |
News Archive
Cambrex Corporation (the "Company") announced that it has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's generic active pharmaceutical ingredient ("API") manufacturing facility located in Milan, Italy in March 2009. The observations noted in the warning letter are primarily related to the collection and maintenance of certain laboratory data.
Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."
For the first time, scientists have discovered that a poorly understood class of RNA produced in a mammal's cells during a respiratory virus attack may affect the outcome of the infection. Their findings are reported today in mBio, a journal of the American Society for Microbiology.
When the space shuttle Discovery lifts off on its final flight Nov. 2, its six astronauts will be joined by 16 rodent passengers on a historic mission of their own. Riding in special self-contained modules that automatically supply them with food and water, the mice will be part of a long-term NASA effort aimed at understanding why spaceflight makes humans more vulnerable to infection by viruses and bacteria.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Cooke, MD 516 Bloomfield Ave, Suite 4, Montclair, NJ 07042-3429 Ph: (973) 509-1500 | Dr John Cooke, MD 516 Bloomfield Ave, Suite 4, Montclair, NJ 07042-3429 Ph: (973) 509-1500 |
News Archive
Cambrex Corporation (the "Company") announced that it has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's generic active pharmaceutical ingredient ("API") manufacturing facility located in Milan, Italy in March 2009. The observations noted in the warning letter are primarily related to the collection and maintenance of certain laboratory data.
Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."
For the first time, scientists have discovered that a poorly understood class of RNA produced in a mammal's cells during a respiratory virus attack may affect the outcome of the infection. Their findings are reported today in mBio, a journal of the American Society for Microbiology.
When the space shuttle Discovery lifts off on its final flight Nov. 2, its six astronauts will be joined by 16 rodent passengers on a historic mission of their own. Riding in special self-contained modules that automatically supply them with food and water, the mice will be part of a long-term NASA effort aimed at understanding why spaceflight makes humans more vulnerable to infection by viruses and bacteria.
› Verified 5 days ago
Dr. David Blady, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 127 Pine St, Montclair, NJ 07042 Phone: 973-743-9555 | |
Dr. Bruce P Friedman, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 207 Inwood Ave, Montclair, NJ 07043 Phone: 973-509-8400 Fax: 973-337-5097 | |
Dr. Laurence Michael Westreich, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 202 Bellevue Ave, Side Entrance, Montclair, NJ 07043 Phone: 973-509-1444 | |
Marie R Badaracco-apolito, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 88 Norwood Ave, Montclair, NJ 07043 Phone: 973-783-5033 Fax: 973-746-2604 | |
Dr. Paul Vincent Kennedy, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 117 Watchung Ave, 2nd Floor, Montclair, NJ 07043 Phone: 973-783-2984 Fax: 973-783-5074 | |
Dr. Edward A Latimer, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 24 Portland Pl, Montclair, NJ 07042 Phone: 973-744-1880 Fax: 973-746-9575 |